Lebrikizumab
Agents For Dermatitis, Excluding Corticosteroids
Sold as EBGLYSS
- Drug class
- Agents For Dermatitis, Excluding Corticosteroids
- Availability
- See label
- Routes
- Subcutaneous
- Markets covered
- 3
- Products on record
- 7
Overview
Lebrikizumab is an active pharmaceutical ingredient in the Agents For Dermatitis, Excluding Corticosteroids group (D11AH). The information below is compiled per regulator from the product labels on record, with direct links to the original documents.
Regulatory status by market
| Market | Regulator | Products | Last revision |
|---|---|---|---|
| GB United Kingdom | MHRA | 4 | May 15, 2026 |
| CA Canada | Health Canada | 2 | February 6, 2026 |
| EU European Union | EMA | 1 | March 20, 2026 |
GBUnited Kingdom· MHRA
4 products
Uses
Ebglyss is indicated for the treatment of moderate-to-severe atopic dermatitis in adults and adolescents 12 years and older with a body weight of at least 40 kg who are candidates for systemic therapy.
How to take
CACanada· Health Canada
2 products
Uses
Ebglyss (lebrikizumab injection) is indicated for the treatment of moderate-to-severe atopic dermatitis in adults and adolescents 12 years of age and older with a body weight of at least 40 kg, whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable.
Ebglyss can be used with or without topical corticosteroids. 3 Pharmacokinetics). Pediatrics (< 12 years of age) and Adolescents (12 to < 18 years who weigh < 40 kg): No data are available to Health Canada; therefore, Health Canada has not authorized an indication for pediatric use in patients < 12 years of age and in adolescents who weigh < 40 kg.
3 Pharmacokinetics).
How to take
EUEuropean Union· EMA
1 product
Uses
Ebglyss is indicated for the treatment of moderate-to-severe atopic dermatitis in adults and adolescents 12 years and older with a body weight of at least 40 kg who are candidates for systemic therapy.
How to take
Sources & citations
- [1]MHRA (UK) · PLGB169730049 · revised May 15, 2026
- [2]Health Canada (DPD) · 02549123 · revised February 6, 2026
- [3]European Medicines Agency · EMEA/H/C/005894 · revised March 20, 2026
Information on this page is compiled from public regulatory records. Drugvu is not affiliated with any regulator or pharmaceutical manufacturer. This is not medical advice. Always consult a qualified healthcare professional.